Diabetes Mellitus, Type 2
Conditions
Brief summary
In summary, the registry should provide novel insight into potential mechanisms of cardiovascular risk reduction in patients treated with Empagliflozin with an indication of intensified glucose lowering therapy based on their HbA1c level.
Detailed description
Patients with diabetes exhibit an increased risk for the development of cardiovascular disease with a significantly impaired prognosis compared to patients without diabetes. Recent data from the EMPA-REG Outcome Trial suggest that treatment with the SGLT-2 inhibitor Empagliflozin reduces cardiovascular events, cardiovascular mortality as well as hospitalization for heart failure in patients with type 2 diabetes and pre-existing cardiovascular disease. Empagliflozin leads to reduction of blood glucose by an increased glucose excretion reduces blood pressure and weight. Still, it remains unclear how empagliflozin led to this pronounced reduction of cardiovascular mortality the EMPA-REG OUTCOME trial. Thus, our registry will analyse various biochemical as well as clinical markers in patients with type 2 diabetes and newly initiated treatment with empagliflozin. and an indication for intensification of glucose lowering therapy with empagliflozin. Patients with an indication for an intensified glucose-lowering therapy (HbA1c \> 7,5%) will receive 10 mg empagliflozin and we will perform biochemical analyses of blood samples including insulin, glucagon as well as metabolites at baseline as well as after 1 and 6 months. In addition we will assess echocardiographical data.
Interventions
None listed
Sponsors
RWTH Aachen University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diabetes mellitus II Patients with whom an empagliflozine treatment is to be initiated from a clinical indication
Exclusion criteria
* Inability to consent to the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The effect of empagliflozine on glucose metabolism | 6 month | HbA1c in % |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of urinary and urogenital infections | 6 month | Urinary infection as reported by the patient CRP (Creactive protein) in mg/dl |
| detection differential regulation of endogenous and exogenous metabolites in addition to circulating proteins by empagliflozin. | 6 month | perform metabolomic and proteomic profiling of serum samples |
| Lipid measurements | 6 month | LDL-C in mg/dl HDL-C in mg/dl TG (triglyceride) in mg/dl |
| - echocardiographic parameters (if collected) with determination of the systolic and diastolic left ventricular function | 6 month | LV-EF (left ventricular ejection fraction) in % LV (left ventricular) global strain |
Outcome results
None listed